Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ERYP ERYTECH Pharma	$3.10	$4.66	$0.30 ▼ $1.47	$105.77M	2.69	93,510 shs	N/A
ITOS iTeos Therapeutics	$9.96 -0.4%	$8.31	$4.80 ▼ $18.13	$382.74M	1.51	677,607 shs	992,118 shs
TECX Tectonic Therapeutic	$19.81 +0.1%	$20.99	$13.70 ▼ $61.07	$369.72M	3.25	174,360 shs	398,720 shs
VIGL Vigil Neuroscience	$7.92	$4.67	$1.31 ▼ $7.95	$369.64M	3.43	742,003 shs	795,906 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ERYP ERYTECH Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
ITOS iTeos Therapeutics	0.00%	+0.20%	+19.76%	+45.35%	-33.11%
TECX Tectonic Therapeutic	0.00%	-11.76%	-19.38%	-6.38%	+1,979,999,900.00%
VIGL Vigil Neuroscience	0.00%	+0.64%	+219.35%	+319.05%	+104.65%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ERYP ERYTECH Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	3.3159 of 5 stars	4.1	4.0	0.0	0.0	0.6	3.3	0.6
TECX Tectonic Therapeutic	2.9106 of 5 stars	3.6	2.0	0.0	0.0	0.6	5.0	0.6
VIGL Vigil Neuroscience	3.7509 of 5 stars	4.0	5.0	0.0	0.0	2.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ERYP ERYTECH Pharma	0.00	N/A	N/A	N/A
ITOS iTeos Therapeutics	2.14	Hold	$15.86	59.21% Upside
TECX Tectonic Therapeutic	3.25	Buy	$82.33	315.62% Upside
VIGL Vigil Neuroscience	2.00	Hold	$10.80	36.36% Upside

Current Analyst Ratings Breakdown

Latest ERYP, ITOS, TECX, and VIGL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/11/2025	TECX Tectonic Therapeutic	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$76.00
6/6/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$87.00
6/5/2025	TECX Tectonic Therapeutic	Lifesci Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/28/2025	ITOS iTeos Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$13.00 ➝ $12.00
5/28/2025	ITOS iTeos Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$10.00 ➝ $12.00
5/28/2025	VIGL Vigil Neuroscience	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$11.00 ➝ $8.00
5/27/2025	VIGL Vigil Neuroscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$14.00 ➝ $8.00
5/23/2025	VIGL Vigil Neuroscience	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/22/2025	VIGL Vigil Neuroscience	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Hold
5/22/2025	VIGL Vigil Neuroscience	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Neutral	$8.00
5/22/2025	VIGL Vigil Neuroscience	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Market Perform

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ERYP ERYTECH Pharma	$32.66M	3.24	N/A	N/A	$0.80 per share	3.88
ITOS iTeos Therapeutics	$35M	10.89	N/A	N/A	$16.16 per share	0.62
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	$9.54 per share	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	$1.75 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ERYP ERYTECH Pharma	-$240K	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	-$134.41M	-$3.04	N/A	N/A	N/A	N/A	-21.37%	-18.55%	8/6/2025 (Estimated)
TECX Tectonic Therapeutic	-$57.98M	-$7.31	N/A	N/A	N/A	N/A	-30.13%	-27.52%	8/13/2025 (Estimated)
VIGL Vigil Neuroscience	-$84.26M	-$2.05	N/A	N/A	N/A	N/A	-111.70%	-74.67%	8/12/2025 (Estimated)

Latest ERYP, ITOS, TECX, and VIGL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	TECX Tectonic Therapeutic	-$1.10	-$0.93	+$0.17	-$0.93	N/A	N/A
5/7/2025	Q1 2025	VIGL Vigil Neuroscience	-$0.53	-$0.49	+$0.04	-$0.49	N/A	N/A
4/28/2025	Q1 2025	ITOS iTeos Therapeutics	-$0.94	-$0.80	+$0.14	-$0.80	$9.35 million	N/A
3/20/2025	Q4 2024	TECX Tectonic Therapeutic	-$1.39	-$0.84	+$0.55	-$0.84	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ERYP ERYTECH Pharma	N/A	N/A	N/A	N/A	N/A
ITOS iTeos Therapeutics	N/A	N/A	N/A	N/A	N/A
TECX Tectonic Therapeutic	N/A	N/A	N/A	N/A	N/A
VIGL Vigil Neuroscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ERYP ERYTECH Pharma	0.32	3.65	3.65
ITOS iTeos Therapeutics	N/A	14.13	14.13
TECX Tectonic Therapeutic	N/A	22.92	22.92
VIGL Vigil Neuroscience	N/A	2.97	2.97

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ERYP ERYTECH Pharma	1.09%
ITOS iTeos Therapeutics	97.16%
TECX Tectonic Therapeutic	62.63%
VIGL Vigil Neuroscience	83.64%

Insider Ownership

Company	Insider Ownership
ERYP ERYTECH Pharma	1.94%
ITOS iTeos Therapeutics	12.50%
TECX Tectonic Therapeutic	38.00%
VIGL Vigil Neuroscience	18.01%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ERYP ERYTECH Pharma	49	34.12 million	33.46 million	Not Optionable
ITOS iTeos Therapeutics	90	38.27 million	33.49 million	Optionable
TECX Tectonic Therapeutic	120	18.67 million	11.58 million	N/A
VIGL Vigil Neuroscience	40	46.67 million	38.27 million	Not Optionable

ERYP, ITOS, TECX, and VIGL Headlines

Recent News About These Companies

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives $10.80 Consensus Price Target from Analysts

June 20 at 1:20 AM | americanbankingnews.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Receives Consensus Rating of "Hold" from Analysts

June 17 at 3:14 AM | marketbeat.com

Two Sigma Investments LP Acquires 41,836 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)

June 12, 2025 | marketbeat.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HURA and VIGL on Behalf of Shareholders

June 9, 2025 | prnewswire.com

Wall Street Analysts Think Vigil Neuroscience (VIGL) Could Surge 26.9%: Read This Before Placing a Bet

June 9, 2025 | zacks.com

Squarepoint Ops LLC Acquires New Shares in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

June 9, 2025 | marketbeat.com

Millennium Management LLC Boosts Holdings in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

June 9, 2025 | marketbeat.com

Jane Street Group LLC Invests $83,000 in Vigil Neuroscience, Inc. (NASDAQ:VIGL)

June 9, 2025 | marketbeat.com

Vigil Neuroscience, Inc. (NASDAQ:VIGL) Holdings Lifted by Two Sigma Advisers LP

June 8, 2025 | marketbeat.com

Vigil Neuroscience halts Phase 2 trial for ALSP treatment

June 5, 2025 | investing.com

Vigil’s TREM2 Antibody for Rare Brain Disease Flunks Phase II Trial

June 5, 2025 | biospace.com

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors ...

June 5, 2025 | morningstar.com

Disappointing results see Vigil Neuro drop iluzanebart development

June 4, 2025 | thepharmaletter.com

VIGIL SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation into Fairness of Vigil Neuroscience, Inc. (NASDAQ: VIGL) Proposed Shareholder Buyout and Encourages Investors to Contact the Firm

June 4, 2025 | prnewswire.com

Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP

June 4, 2025 | globenewswire.com

Should You Buy Vigil Neuroscience, Inc. (VIGL) After Golden Cross?

June 2, 2025 | zacks.com

HC Wainwright Has Bearish Forecast for VIGL FY2026 Earnings

May 30, 2025 | marketbeat.com

Stifel cuts Vigil Neuroscience stock rating, lowers target to $8

May 29, 2025 | investing.com

Vigil Neuroscience (NASDAQ:VIGL) Downgraded by Stifel Nicolaus to Hold

May 29, 2025 | marketbeat.com

Stifel Downgrades Vigil Neuroscience (VIGL)

May 29, 2025 | msn.com

HC Wainwright Reiterates "Neutral" Rating for Vigil Neuroscience (NASDAQ:VIGL)

May 28, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ERYP, ITOS, TECX, and VIGL Company Descriptions

ERYTECH Pharma NASDAQ:ERYP

ERYTECH Pharma S.A., a biopharmaceutical company, focus on development of red blood cell-based therapeutics for cancer and orphan diseases in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing erymethionase, a preclinical product candidate that consists of methionine-?-lyase in red blood cells to target the amino acid metabolism of cancer cells and induce tumor starvation. ERYTECH Pharma S.A. was incorporated in 2004 and is headquartered in Lyon, France.

iTeos Therapeutics NASDAQ:ITOS

$9.96 -0.04 (-0.40%)

Closing price 04:00 PM Eastern

Extended Trading

$9.96 +0.00 (+0.05%)

As of 05:02 PM Eastern

iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.

Tectonic Therapeutic NASDAQ:TECX

$19.81 +0.01 (+0.05%)

Closing price 04:00 PM Eastern

Extended Trading

$19.86 +0.05 (+0.25%)

As of 05:05 PM Eastern

Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA.

Vigil Neuroscience NASDAQ:VIGL

$7.92 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$7.94 +0.02 (+0.25%)

As of 06:35 PM Eastern

Vigil Neuroscience, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. The company is also developing VG-3927, an orally-available small molecule TREM2 agonist to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer's disease in genetically defined subpopulations, which is being evaluated in a Phase 1 clinical trial. It has license agreement with Amgen Inc. to commercially develop, manufacture, use, distribute, and sell therapeutic products containing compounds that bind to TREM2. The company was incorporated in 2020 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time